All In Biotech

Drug Trial Radar · NCT06072183

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, 52-WEEK PLACEBO-CONTROLLED MULTI-CENTER STUDY WITH A DOUBLE-BLIND 52-WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UP/DOSE DOWN TITRATION INVESTIGATING THE EFFICACY, SAFETY, AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,571 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,571

Actual

Start

Nov 8, 2023

Primary completion

Jul 30, 2027

Study completion Jul 30, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 10, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental vitiligo. Vitiligo causes white patches on your skin when the cells that give your skin color are destroyed. Nonsegmental means that it can affect both sides of the body such as both knees and both hands. Ritlecitinib has been tested in earlier clinical studies and has a favorable safety profile. At present there are no approved medications taken by mouth to treat nonsegmental vitiligo. This study is seeking participants who: * Are 18 years of age or older. * are confirmed to have nonsegmental vitiligo for at least 3 months. * Are willing to stop all other treatments that they may be taking for vitiligo. In this study participants will be chosen by chance, like drawing names out of a hat to receive 1 of 3 treatments: •Part I where two different amounts of ritlecitinib (50 mg and 100 mg) are taken once daily. It will be compared to placebo. Placebo is a dummy capsule. It doesn't have any medicine used in the study. Participants receiving placebo who have not responded to treatment after 52 weeks will be given 100 milligrams or 50 milligrams of ritlecitinib for the remaining 52 weeks of the study. • In Part II, participants will only receive 100 milligrams of ritlecitinib. About 1000 participants will take part in Part I and around 450 in Part II globally. The study will compare the experiences of people receiving ritlecitinib to those of the people who do not. This will help see if ritlecitinib is safe and effective. People in Part I will be in this study for about 26 months and people in Part II will be in this study for about 14 months. During the study, participants in part I will need to visit the study site at least 17 times. In part II, participants will visit at least 11 times. Participants will undergo various tests and procedures such as: * vitiligo rating, * physical examinations, * hearing tests, * blood tests, * x-ray, * ECG, * photographs of areas with vitiligo. Participants will be asked to complete questionnaires about their vitiligo.

Conditions

  • Stable Nonsegmental Vitiligo
  • Active Nonsegmental Vitiligo

Interventions

  • RitlecitinibDrug

    100mg Capsule

  • RitlecitinibDrug

    50mg Capsule

  • PlaceboDrug

    Matching capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. US only Co-Primary Endpoints: Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 and Total body Vitiligo Area Scoring Index 50 (T-VASI50) at Week 52Time frame: 52 Weeks
  2. Global (Other than US): Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52Time frame: 52 Weeks
  3. Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events (AEs) leading to discontinuation.Time frame: Baseline through 108 weeks
  4. Incidence of Clinically significant laboratory abnormalities.Time frame: Baseline through 108 weeks

Locations

229 sites in 18 countries. Site status is shown where the registry gives one.

  • Center for Dermatology and Plastic Surgery/CCT Research

    Scottsdale, Arizona

  • Dermatology Trial Associates

    Bryant, Arkansas

  • First OC Dermatology Research Inc

    Fountain Valley, California

  • Seaside Audiology Vertigo & Ear Specialists

    Huntington Beach, California

  • Wallace Medical Group, Inc

    Los Angeles, California

  • Kaiser Permanente

    Oakland, California

  • Cura Clinical Research - Oxnard

    Oxnard, California

  • Mission Dermatology Center

    Rancho Santa Margarita, California

  • Peninsula Research Associates

    Rolling Hills Estates, California

  • Integrative Skin Science and Research

    Sacramento, California

  • University of California San Diego - La Jolla

    San Diego, California

  • Wolverine Clinical Trials

    Santa Ana, California

  • Encore Medical Research of Boynton Beach

    Boynton Beach, Florida

  • FXM Clinical Research - Fort Lauderdale

    Fort Lauderdale, Florida

  • Direct Helpers Research Center

    Hialeah, Florida

  • Clever Medical Research

    Miami, Florida

  • Miami Dermatology and Laser Research

    Miami, Florida

  • SouthCoast Research Center

    Miami, Florida

  • University of Miami Dermatology Clinical Trials Unit

    Miami, Florida

  • University of Miami

    Miami, Florida

  • Bio-Medical Research LLC

    Miami, Florida

  • New Horizon Research Center

    Miami, Florida

  • Skin Research of South Florida

    Miami, Florida

  • Well Pharma Medical Research, Corp.

    Miami, Florida

  • FXM Clinical Research - Miami

    Miami, Florida

  • Health and Life Research Institute

    Miami, Florida

  • University of Miami, Kendall Office

    Miami, Florida

  • Floridian Research Institute Llc

    Miami, Florida

  • Sanitas Research

    Miami, Florida

  • Wellness Clinical Research, LLC

    Miami Lakes, Florida

  • FXM Clinical Research Miramar, LLC

    Miramar, Florida

  • GCP Research, Global Clinical professionals

    St. Petersburg, Florida

  • Advanced Clinical Research Institute

    Tampa, Florida

  • USF Health

    Tampa, Florida

  • Sidney P. Smith, MD, PC dba Georgia Skin & Cancer Clinic

    Savannah, Georgia

  • Endeavor Health Audiology -CHICAGO

    Chicago, Illinois

  • Endeavor Health Audiology -LAKE BLUFF

    Lake Bluff, Illinois

  • Endeavor Health Audiology-NORTHBROOK

    Northbrook, Illinois

  • Endeavor Health Audiology-SKOKIE

    Skokie, Illinois

  • Endeavor Health-Dermatology Clinical Trials Unit

    Skokie, Illinois

Showing 40 of 229 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.